Bausch + Lomb will be responsible for sales, marketing, and other commercialization efforts for biosimilar Lucentis, following regulatory approval in the United States and Canada.
AAM welcomed testimony in which U.S. Trade Representative Robert Lightizer said the free trade agreement currently being negotiated will not contain a provision requiring 10-years of biologic exclusivity.
The FDA has revoked its emergency use authorization for the drugs to treat COVID-19 based on results from a large clinical trial that showed no benefit for decreasing death or speeding recovery.